Materials and Methods: A retrospective descriptive study had been conducted at the Department of Hematology, Cho Ray Hospital during the period from January 2015 to May 2021. Study population included patients who were aged of 18 years and older, newly diagnosed with multiple myeloma, had serum creatinine level greater than 2 mg / dL or decreased glomerular filtration rate eGFR < 60 mL / min/1.73 m2. These patients were treated with regimen of bortezomib, cyclophosphamide, and dexamethasone (VCD).